Abstract
Background: Glycated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes. Previous genome-wide association studies (GWAS) have identified 18 HbA1c-associated genetic variants. These variants proved to be classifiable by their likely biological action, into erythrocytic (also associated with erythrocyte traits) or glycemic (associated with other glucose-related traits). In this study we tested the hypotheses that in a very large scale GWAS, we would identify more genetic variants associated with HbA1c and that HbA1c variants implicated in erythrocytic biology would affect the diagnostic accuracy of HbA1c. We therefore expanded the number of HbA1c-associated loci, and tested the effect of genetic risk-scores comprised of erythrocytic or glycemic variants on incident diabetes prediction, and on prevalent diabetes screening performance. Throughout this multi-ancestry study, we kept a focus on inter-ancestry differences in HbA1c genetics performance that might influence race-ancestry differences in health outcomes.
Methods & Findings: Using genome-wide association meta-analyses in up to 159,940 individuals from 82 cohorts of European, African, East and South Asian ancestry, we identified 60 common genetic variants associated with HbA1c. We classified variants as implicated in glycemic, erythrocytic or unclassified biology and tested whether additive genetic scores of erythrocytic variants (GS-E) or glycemic variants (GS-G) were associated with higher T2D incidence in multi-ethnic longitudinal cohorts (N=33,241). Nineteen glycemic and 22 erythrocytic variants were associated with HbA1c at genome-wide significance. GS-G was associated with higher T2D risk (incidence OR=1.05, 95% CI 1.04 -1.06, per HbA1c-raising allele, P=3×10-29 250 ); whereas GS-E was not (OR=1.00, 95% CI 0.99 - 1.01, P=0.60). In Europeans and Asians, erythrocytic variants in aggregate had only modest effects on the diagnostic accuracy of HbA1c. Yet, in African Americans, the X-linked G6PD G202A variant (T-allele frequency 11%) was associated with an absolute decrease in HbA1c of 0.81%-units (95% CI 253 0.66-0.96) per allele in hemizygous men, and 0.68%-units (95% CI 0.38-0.97) in homozygous women. The G6PD variant may cause ~2% (N=0.65 million, 95% CI 0.55-0.74) of African American adults with T2D to remain undiagnosed when screened with HbA1c. Limitations include the smaller sample sizes for non-European ancestries and the inability to classify approximately one third of the variants. Further studies in large multi-ethnic cohorts with HbA1c, glycemic and erythrocytic traits are required to better determine the biological action of the unclassified variants.
Conclusions: As G6PD deficiency can be clinically silent until illness strikes we recommend investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common. Screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency, may be required to avoid missed or delayed diagnoses.
Methods & Findings: Using genome-wide association meta-analyses in up to 159,940 individuals from 82 cohorts of European, African, East and South Asian ancestry, we identified 60 common genetic variants associated with HbA1c. We classified variants as implicated in glycemic, erythrocytic or unclassified biology and tested whether additive genetic scores of erythrocytic variants (GS-E) or glycemic variants (GS-G) were associated with higher T2D incidence in multi-ethnic longitudinal cohorts (N=33,241). Nineteen glycemic and 22 erythrocytic variants were associated with HbA1c at genome-wide significance. GS-G was associated with higher T2D risk (incidence OR=1.05, 95% CI 1.04 -1.06, per HbA1c-raising allele, P=3×10-29 250 ); whereas GS-E was not (OR=1.00, 95% CI 0.99 - 1.01, P=0.60). In Europeans and Asians, erythrocytic variants in aggregate had only modest effects on the diagnostic accuracy of HbA1c. Yet, in African Americans, the X-linked G6PD G202A variant (T-allele frequency 11%) was associated with an absolute decrease in HbA1c of 0.81%-units (95% CI 253 0.66-0.96) per allele in hemizygous men, and 0.68%-units (95% CI 0.38-0.97) in homozygous women. The G6PD variant may cause ~2% (N=0.65 million, 95% CI 0.55-0.74) of African American adults with T2D to remain undiagnosed when screened with HbA1c. Limitations include the smaller sample sizes for non-European ancestries and the inability to classify approximately one third of the variants. Further studies in large multi-ethnic cohorts with HbA1c, glycemic and erythrocytic traits are required to better determine the biological action of the unclassified variants.
Conclusions: As G6PD deficiency can be clinically silent until illness strikes we recommend investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common. Screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency, may be required to avoid missed or delayed diagnoses.
| Original language | English |
|---|---|
| Article number | e1002383 |
| Number of pages | 30 |
| Journal | PLoS Medicine |
| Volume | 14 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 12 Sept 2017 |
Keywords
- Diabetes Mellitus, Type 2
- Genetic Variation
- Genome-Wide Association Study
- Hemoglobin A, Glycosylated
- Humans
- Phenotype
- Risk
- Meta-Analysis
Access to Document
- Final Published Version
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.